Published in Biotech Business Week, September 19th, 2005
As part of the agreement, Entelos will transfer the technology to Unilever for continued advancement of the model and research in skin sensitization. Entelos will retain full rights to use the platform, including rights for all pharmaceutical applications. Financial terms of the collaboration were not disclosed.
This work forms part of an on-going Unilever program to develop alternative approaches for risk assessment for assuring...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.